Osimertinib Resistance and EGFR Mutations in NSCLC Treatment
Bioengineer
JANUARY 16, 2024
Another genetic change at the C797 residue in the ATP binding region of EGFR’s exon 20 has emerged as a key mechanism of resistance to osimertinib. The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. months vs. 15.2 months, p = 0.01). months, 95% CI 1.3,
Let's personalize your content